JP2013520466A - 二量体iap阻害剤 - Google Patents

二量体iap阻害剤 Download PDF

Info

Publication number
JP2013520466A
JP2013520466A JP2012554332A JP2012554332A JP2013520466A JP 2013520466 A JP2013520466 A JP 2013520466A JP 2012554332 A JP2012554332 A JP 2012554332A JP 2012554332 A JP2012554332 A JP 2012554332A JP 2013520466 A JP2013520466 A JP 2013520466A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
pyridin
pyrrolidin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012554332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520466A5 (enExample
Inventor
クリストファー・ショーン・ストロ−ブ
チェン・ズオリアン
マーク・ジー・パレルモ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013520466A publication Critical patent/JP2013520466A/ja
Publication of JP2013520466A5 publication Critical patent/JP2013520466A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012554332A 2010-02-25 2011-02-23 二量体iap阻害剤 Pending JP2013520466A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US61/308,114 2010-02-25
US33392710P 2010-05-12 2010-05-12
US61/333,927 2010-05-12
US38841010P 2010-09-30 2010-09-30
US61/388,410 2010-09-30
PCT/EP2011/052662 WO2011104266A1 (en) 2010-02-25 2011-02-23 Dimeric iap inhibitors

Publications (2)

Publication Number Publication Date
JP2013520466A true JP2013520466A (ja) 2013-06-06
JP2013520466A5 JP2013520466A5 (enExample) 2014-03-20

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554332A Pending JP2013520466A (ja) 2010-02-25 2011-02-23 二量体iap阻害剤

Country Status (13)

Country Link
US (1) US8445440B2 (enExample)
EP (1) EP2539333A1 (enExample)
JP (1) JP2013520466A (enExample)
KR (1) KR20130010894A (enExample)
CN (1) CN102834389A (enExample)
AR (1) AR080253A1 (enExample)
BR (1) BR112012021291A2 (enExample)
CA (1) CA2790302A1 (enExample)
EA (1) EA201201177A1 (enExample)
MX (1) MX2012009894A (enExample)
TW (1) TW201141846A (enExample)
UY (1) UY33236A (enExample)
WO (1) WO2011104266A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US9453048B2 (en) 2012-08-09 2016-09-27 Bristol-Myers Squibb Company IAP antagonists
EP2917218B1 (en) * 2012-11-09 2017-01-04 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
ES2982449T3 (es) 2013-06-25 2024-10-16 Walter & Eliza Hall Inst Medical Res Miméticos Smac para su uso en el tratamiento de una infección persistente por VIH
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Iapbirドメイン結合化合物
JP2009545613A (ja) * 2006-08-02 2009-12-24 ノバルティス アクチエンゲゼルシャフト Iap阻害剤として有用なsmacペプチド模倣物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
DE60334247D1 (de) 2002-11-27 2010-10-28 Irm Llc Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2007520522A (ja) 2004-02-05 2007-07-26 ノバルティス アクチエンゲゼルシャフト (a)DNAトポイソメラーゼ阻害剤および(b)IAP阻害剤の組み合わせ剤
AU2005218555B2 (en) * 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Iap結合性化合物
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006279929A1 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CN101340947B (zh) * 2005-12-20 2012-09-05 诺瓦提斯公司 Iap-抑制剂和紫杉烷7的组合
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
BRPI0708942A2 (pt) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
MY159563A (en) * 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
KR20090082221A (ko) * 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
MX2009005551A (es) 2006-11-28 2009-06-08 Novartis Ag Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
EP2079309B1 (en) * 2007-04-12 2015-11-11 Joyant Pharmaceuticals Inc SMAC MIMEE DIMERS AND TRIMERS USEFUL AS ANTICANCER AGENTS
AR066348A1 (es) 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
JP2010528587A (ja) 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
TWI471134B (zh) 2007-09-12 2015-02-01 Genentech Inc 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
PL2240506T3 (pl) 2008-01-11 2013-05-31 Genentech Inc Inhibitory IAP
BRPI0906785A2 (pt) 2008-01-24 2015-07-14 Tetralogic Pharm Corp Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
EP2310402A1 (en) 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Iapbirドメイン結合化合物
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2009545613A (ja) * 2006-08-02 2009-12-24 ノバルティス アクチエンゲゼルシャフト Iap阻害剤として有用なsmacペプチド模倣物

Also Published As

Publication number Publication date
UY33236A (es) 2011-09-30
KR20130010894A (ko) 2013-01-29
US20110206690A1 (en) 2011-08-25
BR112012021291A2 (pt) 2016-10-25
US8445440B2 (en) 2013-05-21
MX2012009894A (es) 2012-09-12
WO2011104266A1 (en) 2011-09-01
AR080253A1 (es) 2012-03-21
AU2011219862A1 (en) 2012-09-06
TW201141846A (en) 2011-12-01
CA2790302A1 (en) 2011-09-01
EA201201177A1 (ru) 2013-04-30
EP2539333A1 (en) 2013-01-02
CN102834389A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
US8445440B2 (en) Dimeric IAP inhibitors
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
US8993523B2 (en) Dimeric IAP inhibitors
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
TWI820077B (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
KR20220047810A (ko) 알키닐 퀴나졸린 화합물
EA030539B1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
CN117642416A (zh) 分拣蛋白活性调节剂
WO2021060453A1 (ja) 架橋型光学活性2級アミン誘導体
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
US20130266590A1 (en) Dimeric iap inhibitors
CN102325768A (zh) 治疗疼痛和其他疾病的化合物和方法
AU2020201109A1 (en) NMDA receptor modulators and prodrugs, salts, and uses thereof
CN103373997B (zh) 含有锌结合基的吡啶并萘啶类HDAC和mTOR抑制剂
AU2011219862B2 (en) Dimeric IAP inhibitors
CA3106548A1 (en) Histone demethylase 5 inhibitors and uses thereof
JP2025506445A (ja) Klf2の誘導物質およびその使用方法
WO2014150252A1 (en) Methods of treatment associated with the granulocyte colony-stimulating factor receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140820

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630